Molecular Partners AG
c/o Department of Biochemistry
48 articles with Molecular Partners AG
Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin; therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in January, 2021.
Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy
First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation
Molecular Partners to Share Clinical Data and Expanding Portfolio Strategy at Virtual R&D Day on December 17, 2020
New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected
Molecular Partners AG announced that Dr. Patrick Amstutz, CEO of Molecular Partners, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 3:55 - 4:25 PM Eastern Time.
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420, a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
Interim Management Statement Q3 2020 of Molecular Partners: Emergence of New Opportunities and Strong Platform Validation of DARPin® Therapeutics
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced its interim management statement for the period ending September30, 2020.
Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19
Novartis is harnessing the power of Molecular Partners AG's DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat COVID-19 infection.
10/8/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Molecular Partners Demonstrates Reduction of Mortality and Potent Therapeutic Activity of Anti-COVID-19 DARPin(R) Candidates in Advanced COVID-19 Disease Model
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced supportive preclinical data from in vivo assessments of its DARPin® candidates targeting SARS-CoV-2.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Molecular Partners Presents Preclinical Data Supporting Tumor Localization Mechanism of its CD40 Agonist MP0317 at World Bispecific Summit
MP0317 activates multiple antitumor immune cell types in vitro when in the presence of tumor stroma associated FAP MP0317 mouse surro gate localizes to FAP-expressing tumors and induces strong and durable anti-tumor responses without systemic toxicity, and demonstrates strong anti-tumor immune memory responses ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 24, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-bu
Molecular Partners Completes GMP Manufacturing of Anti-COVID-19 DARPin(R) Candidate MP0420 for Clinical Use
Molecular Partners AG announced the completion of initial Good Manufacturing Practice manufacturing runs of its tri-specific, antiviral DARPin® candidate for COVID-19, named MP0420.
Molecular Partners AG announced that Patrick Amstutz, chief executive officer, will be presenting at the HC Wainwright 22nd Annual Global Investments Conference taking place September 14-16, 2020, as well as participating in a fireside chat at the Morgan Stanley Global Healthcare Conference taking place September 14-18, 2020.
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, announced its corporate highlights and unaudited financial results for the first half-year of 2020.
8/13/2020Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Molecular Partners Announces Agreement with Swiss Government, Securing Rights to Purchase Doses of First Anti-COVID-19 DARPin(R) Program
Molecular Partners AG announced the reservation by the Swiss Federal Office of Public Health: Bundesamt für Gesundheit of a defined number of initial doses of the company's multi-specific DARPin® anti-COVID-19 candidate, MP0420.
Molecular Partners AG announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency and the Japanese Regulatory Agency for abicipar pegol, a novel DARPin therapeutic for patients with neovascular age-related macular degeneration.
Global Biopharmaceutical Contract Development and Manufacturing Organization AGC Biologics is partnering with clinical-stage biotech company Molecular Partners AG to develop a new class of custom-built protein therapeutics known as DARPin®.